Pictet Asset Management (Switzerland)’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-251,806	Closed	-$27M	–	2053
2023 Q1	$27M	Buy	251,806 +248,839	+8,387%	+$28.6M	0.03%	393
2022 Q4	$326K	Buy	+2,967	New	+$192K	﹤0.01%	1456

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s RXDX Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 251,806 shares — an estimated $27M sold.

Pictet Asset Management (Switzerland) first reported a position in RXDX in Q4 2022 and held it in 2 quarters. The position peaked at $27M in Q1 2023. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Pictet Asset Management (Switzerland) reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Pictet Asset Management (Switzerland) sold 251,806 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $27M.
Pictet Asset Management (Switzerland) first reported a position in Prometheus Biosciences, Inc. Common Stock in Q4 2022 and held it in 2 quarters.
Pictet Asset Management (Switzerland)'s Prometheus Biosciences, Inc. Common Stock position peaked at $27M in Q1 2023.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.